NovaBay Pharmaceuticals Inc
NBY5.250USD
+2.300+77.97%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
31.56MMarket Cap
0.85P/E TTM
More Details of NovaBay Pharmaceuticals Inc Company
NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
NovaBay Pharmaceuticals Inc Info
Ticker SymbolNBY
Company nameNovaBay Pharmaceuticals Inc
IPO dateOct 26, 2007
CEOKazley (Michael John)
Number of employees14
Security typeOrdinary Share
Fiscal year-endOct 26
Address2000 Powell St Ste 1150
CityEMERYVILLE
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code94608-1804
Phone15108998800
Websitehttps://novabay.com/
Ticker SymbolNBY
IPO dateOct 26, 2007
CEOKazley (Michael John)
Company Executives of NovaBay Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Swan Sit
Ms. Swan Sit
Independent Director
Independent Director
933.00
+914.13%
Mr. Justin M. Hall, Esq.
Mr. Justin M. Hall, Esq.
Vice President - Business Development, General Counsel, Corporate Secretary
Vice President - Business Development, General Counsel, Corporate Secretary
67.00
-88.45%
Mr. Paul E. Freiman, Ph.D.
Mr. Paul E. Freiman, Ph.D.
Director
Director
--
--
Dr. Yenyou (Jeff) Zheng, Ph.D.
Dr. Yenyou (Jeff) Zheng, Ph.D.
Independent Director
Independent Director
--
--
Mr. Tommy Law
Mr. Tommy Law
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
-100.00%
Capt. Jody Cain
Capt. Jody Cain
IR Contact Officer
IR Contact Officer
--
--
Mr. Michael Kazley
Mr. Michael Kazley
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Swan Sit
Ms. Swan Sit
Independent Director
Independent Director
933.00
+914.13%
Mr. Justin M. Hall, Esq.
Mr. Justin M. Hall, Esq.
Vice President - Business Development, General Counsel, Corporate Secretary
Vice President - Business Development, General Counsel, Corporate Secretary
67.00
-88.45%
Mr. Paul E. Freiman, Ph.D.
Mr. Paul E. Freiman, Ph.D.
Director
Director
--
--
Dr. Yenyou (Jeff) Zheng, Ph.D.
Dr. Yenyou (Jeff) Zheng, Ph.D.
Independent Director
Independent Director
--
--
Mr. Tommy Law
Mr. Tommy Law
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
-100.00%
Capt. Jody Cain
Capt. Jody Cain
IR Contact Officer
IR Contact Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
Avenova
8.67M
88.67%
Other products
1.07M
10.98%
Other revenue, net
34.00K
0.35%
NeutroPhase
0.00
0.00%
By RegionUSD
Name
Revenue
Proportion
United States
9.78M
100.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Avenova
8.67M
88.67%
Other products
1.07M
10.98%
Other revenue, net
34.00K
0.35%
NeutroPhase
0.00
0.00%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Poplar Point Capital Management LLC
0.81%
The Vanguard Group, Inc.
0.07%
Geode Capital Management, L.L.C.
0.04%
State Street Investment Management (US)
0.02%
Apollon Wealth Management, LLC
0.02%
Other
99.04%
Shareholders
Shareholders
Proportion
Poplar Point Capital Management LLC
0.81%
The Vanguard Group, Inc.
0.07%
Geode Capital Management, L.L.C.
0.04%
State Street Investment Management (US)
0.02%
Apollon Wealth Management, LLC
0.02%
Other
99.04%
Shareholder Types
Shareholders
Proportion
Hedge Fund
0.81%
Investment Advisor
0.10%
Investment Advisor/Hedge Fund
0.06%
Research Firm
0.01%
Other
99.01%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
38
1.37M
22.81%
-82.54K
2025Q2
43
1.43M
24.52%
+210.59K
2025Q1
42
1.34M
22.96%
+376.59K
2024Q4
40
546.91K
11.19%
+390.20K
2024Q3
42
126.44K
2.60%
+79.02K
2024Q2
44
12.01K
0.89%
-33.08K
2024Q1
44
12.73K
1.48%
-22.10K
2023Q4
45
34.29K
18.48%
+25.73K
2023Q3
47
15.18K
15.11%
-444.00
2023Q2
47
9.53K
10.53%
-5.30K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Poplar Point Capital Management LLC
1.02M
16.99%
--
--
Sep 03, 2025
The Vanguard Group, Inc.
270.00
0%
--
--
Aug 31, 2025
Geode Capital Management, L.L.C.
33.82K
0.56%
-1.17K
-3.35%
Jun 30, 2025
Tower Research Capital LLC
5.45K
0.09%
-6.00
-0.11%
Jun 30, 2025
Freiman (Paul Edward)
935.00
0.02%
+763.00
+443.60%
Sep 22, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
Date
Type
Ratio
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
FAQs
Who are the top five shareholders of NovaBay Pharmaceuticals Inc?
The top five shareholders of NovaBay Pharmaceuticals Inc are:
Poplar Point Capital Management LLC holds 1.02M shares, accounting for 16.99% of the total shares.
The Vanguard Group, Inc. holds 270.00 shares, accounting for 0.00% of the total shares.
Geode Capital Management, L.L.C. holds 33.82K shares, accounting for 0.56% of the total shares.
Tower Research Capital LLC holds 5.45K shares, accounting for 0.09% of the total shares.
Freiman (Paul Edward) holds 935.00 shares, accounting for 0.02% of the total shares.
Poplar Point Capital Management LLC holds 1.02M shares, accounting for 16.99% of the total shares.
The Vanguard Group, Inc. holds 270.00 shares, accounting for 0.00% of the total shares.
Geode Capital Management, L.L.C. holds 33.82K shares, accounting for 0.56% of the total shares.
Tower Research Capital LLC holds 5.45K shares, accounting for 0.09% of the total shares.
Freiman (Paul Edward) holds 935.00 shares, accounting for 0.02% of the total shares.
What are the top three shareholder types of NovaBay Pharmaceuticals Inc?
The top three shareholder types of NovaBay Pharmaceuticals Inc are:
Poplar Point Capital Management LLC
The Vanguard Group, Inc.
Geode Capital Management, L.L.C.
Poplar Point Capital Management LLC
The Vanguard Group, Inc.
Geode Capital Management, L.L.C.
How many institutions hold shares of NovaBay Pharmaceuticals Inc (NBY)?
As of 2025Q3, 38 institutions hold shares of NovaBay Pharmaceuticals Inc, with a combined market value of approximately 1.37M, accounting for 22.81% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -1.70%.
What is the biggest source of revenue for NovaBay Pharmaceuticals Inc?
In FY2024, the Avenova business generated the highest revenue for NovaBay Pharmaceuticals Inc, amounting to 8.67M and accounting for 88.67% of total revenue.
